ASA Partners with AACR, FDA to Host Workshop
The American Association for Cancer Research, American Statistical Association, and US Food and Drug Administration hosted a workshop July 18 dedicated to discussions about the overall survival and other endpoints in oncology clinical trials.
The workshop, held in Bethesda, Maryland, drew more than 3,000 people from 10 countries who also aligned expectations on overall survival assessment for cancer drugs from scientific and regulatory perspectives and discussed best practices for conducting clinical research and applying statistical methods. The workshop included five sessions, with topics ranging from trial design considerations to pre-specified analysis and post-hoc analysis of overall survival to incorporating overall survival into the overall benefit-risk assessment.
The event provided the ASA with the opportunity to partner with government agencies and other professional organizations on cross-disciplinary scientific programs. Oncologists and statisticians fostered collaborations, and the ASA was able to reinforce its mission to promote the practice and profession of statistics.
From left: Ruixiao Lu of Alumis (workshop co-chair), Richard Pazdur of the FDA, Ken Anderson of the American Association for Cancer Research (workshop co-chair), Lisa Rodriguez of the FDA (workshop co-chair), and Nicole Gormley of the FDA (workshop co-chair)
The Partnership for Clinical Research and Statistics, a newly formed ASA interest group, facilitated the workshop. The partnership serves as a platform for the ASA to collaborate with professional clinical organizations and regulatory agencies such as the FDA.
View slide presentations and recordings from the workshop.
For more information, contact Ruixiao Lu at [email protected].
